Classification
Product TypeIngredient
Product FormPowder or granules
Industry PositionFood Additive (Colour)
Market
Erythrosine (INS 127; E 127; FD&C Red No. 3) is an iodinated synthetic xanthene food colour used to impart a bright cherry-red/pink hue in selected applications. Global market access is primarily shaped by regulation rather than agronomic seasonality, with Codex GSFA provisions covering limited food categories and the EU authorising only highly restricted uses (e.g., certain candied/cocktail cherries). The United States issued an order on January 15, 2025 to revoke authorisations for use in food and ingested drugs, with compliance timelines extending into 2027–2028, driving reformulation and substitution demand. Publicly available trade statistics are typically not product-specific because erythrosine is commonly aggregated under broader “synthetic organic colouring matter” customs headings, limiting transparent global flow visibility.
Market GrowthMixed (near- to medium-term)Regulatory-driven contraction in some major markets alongside continued niche demand where permitted
Specification
Physical Attributes- Red powder or granules (food additive specification description in EU Regulation (EU) No 231/2012).
- Sold as a water-soluble dye (typically disodium salt form) and also used in aluminium lake forms where permitted (EU Regulation (EU) No 231/2012; PubChem entries for erythrosine sodium and aluminium lake).
Compositional Metrics- EU purity specification includes assay for total colouring matters (minimum content specified in Regulation (EU) No 231/2012) and identification via characteristic absorbance in aqueous solution (Regulation (EU) No 231/2012).
- JECFA maintains specifications and an ADI for erythrosine (WHO JECFA database entry for INS 127).
- U.S. CFR identity/specification language historically defines FD&C Red No. 3 as the disodium salt (21 CFR § 74.303).
Grades- Food additive grade aligned to published purity specifications (e.g., EU Regulation (EU) No 231/2012; JECFA specifications referenced in WHO JECFA database).
- Where applicable, sold as an identifiable colour additive with jurisdiction-specific compliance requirements (e.g., FDA colour additive framework; Codex INS 127 listing).
ProcessingManufactured by iodination of fluorescein (EU Regulation (EU) No 231/2012 definition).Codex GSFA provisions list maximum use levels by food category for INS 127 where adopted into national regulations (Codex GSFA Food Additives Index entry for Erythrosine (127)).
Supply Chain
Value Chain- Chemical manufacture (iodination of fluorescein) -> purification/standardisation to published specifications -> quality testing -> packaging -> distribution to food and pharmaceutical formulators -> finished goods manufacturing -> label declaration per local rules (EU Regulation (EU) No 231/2012; FDA colour additive framework; Codex INS listing).
Demand Drivers- Use in specific permitted food categories requiring a bright cherry-red hue (examples include candies, cakes/frostings/icings in historical U.S. usage descriptions; Codex GSFA provisions include candied fruit/cocktail cherries, chewing gum, and decorations/toppings/sweet sauces categories) (FDA; Codex GSFA).
- Regulatory change and reformulation: substitution to other colours in markets phasing out or restricting erythrosine (FDA order issued January 15, 2025 for U.S. food and ingested drugs).
Risks
Regulatory Compliance HighMarket access can change abruptly due to safety- and law-driven regulatory actions. The U.S. FDA issued an order on January 15, 2025 to revoke authorisations for FD&C Red No. 3 (erythrosine) in food and ingested drugs, with reformulation deadlines extending into 2027–2028; this creates immediate compliance, reformulation, and import clearance risk for global supply chains serving the U.S. market.Maintain jurisdiction-by-jurisdiction additive allowlists and reformulation readiness; validate colour alternatives and update label/ingredient declarations ahead of compliance dates.
Market Access MediumApprovals are highly jurisdiction-specific and narrow in some major markets. In the EU, erythrosine (E 127) is authorised only for very limited uses (e.g., certain candied/cocktail cherries), while Codex GSFA provisions specify maximum levels by food category; products formulated for one market may be non-compliant in another.Design formulations to meet the strictest target-market rules; segregate SKUs and specifications by destination market and document legal basis (Codex/EU/FDA) for each use.
Food Safety MediumCompliance depends on meeting published identity and purity specifications and controlling impurities/quality parameters. EU specifications define identity, manufacturing basis, and minimum assay/characterisation requirements, while FDA/CFR and JECFA references provide additional specification and safety evaluation anchors; non-conforming lots can trigger recalls or border rejections.Qualify suppliers against JECFA/EU/FDA-relevant specs; require certificates of analysis and conduct periodic independent verification testing aligned to the applicable regulatory specification.
FAQ
What is erythrosine called in major international regulatory systems?Erythrosine is commonly listed as INS 127 in Codex (Codex Alimentarius) and as E 127 in the European Union. In the United States it has been referred to as FD&C Red No. 3 (also called Red Dye No. 3), which the FDA identifies as erythrosine.
Is erythrosine permitted for use in foods globally?No. Permissions vary by jurisdiction: Codex GSFA lists specific food categories and maximum levels for INS 127, the EU authorises E 127 only for very limited uses (such as certain candied/cocktail cherries), and the U.S. FDA issued an order on January 15, 2025 to revoke authorisations for FD&C Red No. 3 in food and ingested drugs with compliance timelines extending into 2027–2028.
Why is erythrosine considered a high regulatory-risk colour additive?Erythrosine has a long history of safety re-evaluation and regulatory action. EFSA discusses thyroid tumour findings in rats and concludes the EU’s restricted authorisation remains appropriate, while the FDA cites legal requirements (including the Delaney Clause) in its January 15, 2025 order revoking authorisations for use in food and ingested drugs in the U.S.